STOCK TITAN

Farallon group revises Beta Bionics (BBNX) 9.9% ownership and leadership roles

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Beta Bionics, Inc. received an updated Schedule 13G/A from Farallon-affiliated investors and Zone Healthcare Holdings, LLC. The filing reports Zone Healthcare Holdings and Farallon Capital Management, L.L.C. each beneficially owning 3,277,220 common shares, or 7.4% of the company.

Farallon’s individual reporting persons, including multiple senior investment professionals, are each reported as beneficial owners of 4,379,920 shares, representing 9.9% of the common stock. The amendment records governance changes: effective December 31, 2025, Richard B. Fried, Rajiv A. Patel, and William Seybold ceased to be beneficial owners, while effective January 1, 2026, Avner A. Husen became a deemed beneficial owner through his new management roles.

The group files under Rule 13d-1(c) and certifies the shares were not acquired to change or influence control of Beta Bionics.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Zone Healthcare Holdings, LLC
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its Manager
Date:02/09/2026
Farallon Capital Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/09/2026
Farallon Capital Institutional Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/09/2026
Farallon Capital Institutional Partners II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/09/2026
Farallon Capital Institutional Partners III, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/09/2026
Four Crossings Institutional Partners V, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:02/09/2026
Farallon Capital Offshore Investors II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/09/2026
Farallon Capital (AM) Investors, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/09/2026
Farallon Capital F5 Master I, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:02/09/2026
Farallon Capital Management, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member
Date:02/09/2026
Farallon Partners, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member
Date:02/09/2026
Farallon F5 (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:02/09/2026
Farallon Institutional (GP) V, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:02/09/2026
Dapice Joshua J.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Dreyfuss, Philip D.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Dunn Hannah E.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn
Date:02/09/2026
Fried, Richard B
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Gehani, Varun N.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Giauque, Nicolas
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Husen, Avner A.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Kim, David T.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Linn, Michael G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Luo Patrick (Cheng)
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Patel, Rajiv A.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Roberts, Jr., Thomas G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Saito Edric C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Seybold, William
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Short Daniel S.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Spokes, Andrew J. M.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Warren, John R.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Wehrly, Mark C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Exhibit Information

Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

FAQ

What does the Beta Bionics (BBNX) Schedule 13G/A Amendment No. 3 report?

The amendment reports updated ownership by Farallon-affiliated entities and Zone Healthcare Holdings, LLC in Beta Bionics common stock. It details share amounts and percentages, management structure links, and confirms the holdings are reported as passive investments under Rule 13d-1(c), not for controlling the company.

How many Beta Bionics shares do Farallon and Zone Healthcare Holdings report owning?

Zone Healthcare Holdings, LLC and Farallon Capital Management, L.L.C. each report beneficial ownership of 3,277,220 Beta Bionics common shares, representing 7.4% of the outstanding common stock. Several Farallon individual reporting persons each report beneficial ownership of 4,379,920 shares, equal to 9.9% of the class.

Which ownership changes in Farallon’s leadership are disclosed for Beta Bionics (BBNX)?

The amendment states that, effective December 31, 2025, Richard B. Fried, Rajiv A. Patel, and William Seybold ceased serving in management roles and may no longer be deemed beneficial owners. Effective January 1, 2026, Avner A. Husen assumed comparable roles and may be deemed a beneficial owner.

Why is Avner A. Husen now a deemed beneficial owner of Beta Bionics shares?

Avner A. Husen became a member of Farallon Capital Management, the Farallon General Partner, and a manager of the FCIP V and F5MI general partners effective January 1, 2026. These roles grant investment discretion over funds holding Beta Bionics shares, so he may be deemed a beneficial owner.

Are Farallon and Zone Healthcare Holdings seeking control of Beta Bionics with these holdings?

The reporting persons certify the Beta Bionics shares were not acquired and are not held to change or influence control of the company. They state the holdings are not in connection with any control-seeking transaction, other than potential activities related to director nomination under Rule 14a-11.

Under which rule is the Beta Bionics Schedule 13G/A filed by the Farallon group?

The reporting persons state they are filing under Rule 13d-1(c), which covers certain passive investors. They also note they neither affirm nor disclaim the existence of a group among them, and each reporting person is a beneficial owner only of the securities listed on its own cover page.
Beta Bionics, Inc.

NASDAQ:BBNX

BBNX Rankings

BBNX Latest News

BBNX Latest SEC Filings

BBNX Stock Data

650.68M
43.46M
6.49%
104.92%
7.16%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
IRVINE